

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Carlos Plata-Salaman

Serial No. : 10/056,828

Art Unit: 1623

Filed : January 24, 2002

Examiner: T.C. McIntoshIII

For : TREATMENT OF NEUROLOGICAL DYSFUNCTION COMPRISING  
FRUCTOPYRANOSE SULFAMATES AND ERYTHROPOIETIN

I hereby certify that this correspondence is being transmitted via  
The Office electronic filing system in accordance with 37 CFR 1.6(a)(4)

May 15, 2007  
(Date of Transmission)

Yunling Ren  
(Name of applicant, assignee, or Registered Representative)

/Yunling Ren/  
(Signature)

May 15, 2007  
(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This copy is supplemental to the Information Disclosure  
Statement mailed on March 5, 2002.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37  
C.F.R. §§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

Applicant(s) reserve(s) the right to establish the  
patentability of the claimed invention over any of the  
information provided herewith, and/or to prove that this  
information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1573USNP/YR. This form is submitted in triplicate.

Respectfully submitted,

/Yunling Ren/\_\_\_\_\_  
Yunling Ren  
Reg. No. 47,019  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-3385